Interim report
Page 1
CONSOLIDAT ED FINANCIAL REPORT [IFRS] for the Three-Month Period Ended June 30, 2026 August 3, 2026 Eisai Co., Ltd. Stock exchange listing: Tokyo Stock Exchange (TSE) TSE Code: 4523 URL: https://www.eisai.com Re presentative: Haruo Naito, Representative Corporate Officer & CEO Contact: Teruyuki Masaka, Vice President, Corporate Communications Telephone: +81-3-3817-5120 Expected date of dividend payment commencement: — Preparation of supplementary explanatory material: Yes Financial results briefing held: Yes (Figures are rounded to the nearest million yen) 1. Consolidated Financial Results for the Three-Month Period Ended June 30, 2026 (1) Consolidated Operating Results ( Percentage figures show year on year change) Rev enue Operating profit Profit before income taxes Profit for the period Profit for the period attributable to owners of the parent Comprehensive income for the period (¥ million) (%) (¥ million) (%) (¥ million) (%) (¥ million) (%) (¥ million) (%) (¥ million) (%) Three-month period ended June 30, 2026 234,330 15.6 24,728 19.2 25,283 12.8 19,151 24.9 18,242 26.0 31,177 181.7 Three-month period ended June 30, 2025 202,651 7.2 20,744 54.7 22,404 40.3 15,337 33.2 14,474 36.8 11,067 -79.0 Ear nings per share attributable to owners of the parent (basic) Earnings per share attributable to owners of the parent (diluted) (¥) (¥) Three-month period ended June 30, 2026 64.71 — Three-month period ended June 30, 2025 51.35 — (2) Cons olidated Financial Position Total assets Total equity Equity attributable to owners of the parent Ratio of equity attributable to owners of the parent Equity per share attributable to owners of the parent (¥ million) (¥ million) (¥ million) (%) (¥) As of June 30, 2026 1,558,091 933,169 906,564 58.2 3,216.02 As of March 31, 2026 1,449,113 925,124 898,992 62.0 3,189.15
Page 2
2. Dividends Annual dividend per share End of Q1 End of Q2 End of Q3 End of FY Total (¥) (¥) (¥) (¥) (¥) FY 2025 — 80.00 — 80.00 160.00 FY 2026 — FY 2026 (Forecast) 80.00 — 80.00 160.00 (Note) Revisions to the latest dividend forecast: No 3. Consolidated Financial Forecast for Fiscal 2026 (April 1, 2026 – March 31, 2027) (Percentage figures show year on year change) Revenue Operating profit Profit before income taxes Profit for the year Profit for the year attributable to owners of the parent Earnings per share attributable to owners of the parent (basic) (¥ million) (%) (¥ million) (%) (¥ million) (%) (¥ million) (%) (¥ million) (%) (¥) Fiscal Year 883,500 7.0 70,000 58.6 74,000 45.1 54,000 33.3 52,300 35.6 185.00 (Note) Revisions to the latest financial forecast: No * Explanatory Notes (1) Changes in number of significant subsidiaries during the period (changes in specified subsidiaries resulting in a change in scope of consolidation) : No (2) Changes in accounting policies and accounting estimates: 1) Changes in accounting policies required by IFRS: Yes 2) Changes in accounting policies other than 1): No 3) Changes in accounting estimates: No (3) Number of shares issued (common shares): 1) Number of shares issued (including treasury shares) As of June 30, 2026 291,649,149 As of March 31, 2026 291,649,149 2) Number of treasury shares As of June 30, 2026 9,190,146 As of March 31, 2026 9,535,293 3) Weighted average number of shares outstanding For the three-month period ended June 30, 2026 281,890,450 For the three-month period ended June 30, 2025 281,887,947 The Company’s shares held through a trust (568,840 shares) are not included in the number of treasury shares as of the end of the period, but are included in the average number of shares outstanding as treasury shares that are deducted from the calculation of earnings per share. * Review of attached Interim Consolidated Financial Statements by independent auditors: No * Explanation concerning the appropriate use of results forecast and other special instructions: (Caution concerning forward-looking statements ) Materials and information provided in this financial disclosure may contain “forward-looking statements” based on expectations, business goals , estimates, forecasts and assumptions that are subject to risks and uncertainties as of the publication date of these materials. Accordingly, actual outcomes and results may differ materially from these statements depending on a number of important factors. Please refer to page 7 f or details with regard to the assumptions and other related matters concerning the consolidated financial forecast. (Methods for obtaining supplementary materials and content of financial results disclosure meeting) Supplementary materials are attached to this financial report. The Company plans to hold a financial results disclosure meeting for institutional investors and securities analysts on Monday, August 3, 2026. The handouts for the disclosure meeting will be made available on the Company’s website.
Page 3
Supplemental Materials: Table of Contents 1. Qualitative Information regarding Financial Results for the Period ( Page) (1) Operating Results ･･･････････ 2 (2) Financial Position ･･･････････ 4 (3) Research & Development Pipeline, Alliances , and Other Events ･･･････････ 5 (4) Information on Outlook for the Future including Financial Forecast ･･･････････ 7 2. Condensed Interim Consolidated Financial Statements and Major Notes (1) Condensed Interim Consolidated Statement of Income ･･･････････ 8 (2) Condensed Interim Consolidated Statement of Comprehensive Income ･･･････････ 9 (3) Condensed Interim Consolidated Statement of Financial Position ･･･････････ 10 (4) Condensed Interim Consolidated Statement of Changes in Equity ･･･････････ 12 (5) Condensed Interim Consolidated Statement of Cash Flows ･･･････････ 14 (6) Notes to Condensed Interim Consolidated Financial Statements (Going Concern) ･･･････････ 15 (Changes in Accounting Policies) ･･･････････ 15 (Segment Information) ･･･････････ 16 (Consolidated Statement of Income) ･･･････････ 17 (Consolidated Statement of Cash Flows ) ･･･････････ 17 (Significant Subsequent Events) ･･･････････ 17 1
Page 4
1．Qualitative Information regarding Financial Results for the Period (1) Operating Results [Revenue and Profit] 〇 Eisai Co., Ltd. (“the Company”) and its affiliates (collectively referred to as “the Group”) recorded the following consolidated financial results for the three-month period ended June 30, 2026. (¥billion) Three-month period ended June 30, 2025 Three-month period ended June 30, 2026 % Change Revenue 202.7 234.3 +15.6% Cost of sales 42.6 51.1 +19.9% Gross profit 160.1 183.2 +14.5% Selling, general and administrative expenses 100.2 114.8 +14.6% Research and development expenses 38.8 43.7 +12.7% Operating profit 20.7 24.7 +19.2% Profit before income taxes 22.4 25.3 +12.8% Profit for the period 15.3 19.2 +24.9% Profit for the period attributable to owners of the parent 14.5 18.2 +26.0% (Reference) Core operating profit 21.7 24.7 +13.9% (Core Operating Profit: an indicator of fundamental earning calculated by excluding temporary income and expenses from operating profit; see page 2 of the Reference Data for details of the adjustments .) ○ Revenue significantly in creased due to continued growth of anticancer agent Lenvima, Alzheimer’s disease (AD) treatment Leqembi, and insomnia treatment Dayvigo, in addition to the depreciation of the Japanese yen. R evenue of pharmaceutical business came to ¥230.9 billion (up 16.4% year on year). ○ Regarding revenue from major products, revenue for Lenvima, Leqembi, and Dayvigo all achieved significant growth, coming to ¥97.3 billion (up 15.9% year on year), ¥29.3 billion (up 26.7% year on year), and ¥18.9 billion (up 37.9% year on year), respectively. ○ Selling, general and administrative expenses increased due to shared profit paid to Merck & Co., Inc., Rahway, NJ, USA following Lenvima’s revenue growth and proactive resource investment for Leqembi. ○ Research and development expenses increased due to continuous proactive resource investment in important projects such as Leqembi, anti-microtubule binding region (MTBR) tau antibody E2814, and novel selective orexin 2 receptor agonist E2086. ○ Operating profit significantly increased due to growth of major products, absorbing the impact of stockpiling by distributors in China in the same period of the previous fiscal year. Core operating profit, which indicates fundamental earning, came to ¥24.7 billion (up 13.9% year on year). 2
Page 5
[ Performance by Segment] ( Revenue for each segment indicates revenue from external customers) The Group’s business is comprised of pharmaceutical business and other business. The pharmaceutical business is organized into the following five reporting segments in this report: Japan, Americas (North America), China, EMEA (Europe, the Middle East, Africa, Russia and Oceania), and East Asia Global South (primarily South Korea, Taiwan, India, ASEAN, Central and South America, and South Africa). <Japan pharmaceutical business> ○ Total revenue came to ¥57.9 billion (up 3.4% year on year), with a segment profit of ¥21.0 billion (up 8.1% year on year). Breakdown of revenue was ¥52.7 billion (up 4.1% year on year) from prescription medicines and ¥5.2 billion (down 3.5% year on year) from OTC and others. ○ Regarding revenue by product, revenue for Dayvigo and Leqembi achieved significant growth coming to ¥12.4 billion (up 13.4% year on year) and ¥6.1 billion (up 10.9% year on year), respectively. Revenue for Lenvima achieved growth coming to ¥3.7 billion (up 3.0% year on year). Revenue for JAK ( Janus kinase) inhibitor Jyseleca, chronic constipation treatment MOVICOL and chronic constipation treatment Goofice achieved significant growth coming to ¥5.4 billion (up 25.2% year on year), ¥3.0 billion (up 48.3% year on year) and ¥2.6 billion (up 18.2 % year on year), respectively . Revenue for antiepileptic agent Fycompa achieved growth coming to ¥2.2 billion (up 5.8% year on year). In OTC and others, revenue for Chocola BB Group achieved growth coming to ¥3.9 billion (up 1.1% year on year). <Americas pharmaceutical business> ○ Total revenue came to ¥86.6 billion (up 22.3% year on year), with a segment profit of ¥51.9 billion (up 25.0% year on year). ○ Regarding revenue by product, revenue for Lenvima, Leqembi and Dayvigo achieved significant growth coming to ¥66.5 billion (up 14.5% year on year), ¥15.5 billion (up 70.5% year on year) and ¥3.3 billion (up 74.5% year on year), respectively. <China pharmaceutical business> ○ Total revenue came to ¥42.5 billion (up 16.6% year on year), with a segment profit of ¥21.2 billion (up 18.2% year on year). ○ Regarding revenue by product, revenue for Lenvima came to ¥6.8 billion (down 0.9% year on year). Revenue for Leqembi came to ¥4.8 billion (down 37.3% year on year), due to the impact of stockpiling by distributors in the same period of the previous fiscal year. Revenue for Dayvigo came to ¥1.4 billion (¥0.1 billion in the same period of the previous fiscal year). Revenue for vertigo and equilibrium disturbance treatment Merislon and peripheral neuropathy treatment Methycobal achieved significant growth coming to ¥5.1 billion (up 67.1% year on year), and ¥3.7 billion (up 27.7% year on year), respectively. 3
Page 6
<EMEA pharmaceutical business> ○ Total revenue came to ¥23.6 billion (up 24.4% year on year), with a segment profit of ¥12.5 billion (up 51.8% year on year). ○ Regarding revenue by product , revenue for Lenvima/Kisplyx , Leqembi and Fycompa all achieved significant growth coming to ¥15.1 billion (up 36.6% year on year), ¥0.5 billion (up 341.2% year on year), and ¥4.8 billion (up 18.3% year on year), respectively. ○ Leqembi was launched in Belgium and Australia in June 2026. <East Asia Global South pharmaceutical business> ○ Total revenue came to ¥20.2 billion (up 25.3% year on year), with a segment profit of ¥9. 5 billion (up 15.0% year on year). ○ Regarding revenue by product, revenue for Lenvima and Leqembi achieved significant growth coming to ¥5.2 billion (up 20.3% year on year) and ¥2.4 billion (up 214.0% year on year), respectively. Revenue for Alzheimer’s disease treatment Aricept came to ¥3.6 billion (down 4.0% year on year). ○ Leqembi was launched in Brazil and India in June 2026. (2) Financial Position [Assets, Liabilities, and Equity] ○ Total assets as of the end of the period amounted to ¥1,558.1 billion (up ¥109.0 billion from the end of the previous fiscal year). Inventories increased due to proceeding the production of Leqembi and others, in addition to an increase in trade and other receivables mainly due to an increase in revenue. ○ Total liabilities as of the end of the period amounted to ¥624.9 billion (up ¥100.9 billion from the end of the previous fiscal year). Bonds and borrowings increased due to unsecured straight bond issuance and others. ○ Total equity as of the end of the period amounted to ¥933.2 billion (up ¥8.0 billion from the end of the previous fiscal year). E xchange differences on translation of foreign operations increased due to impact of the exchange rate. ○ As a result of the above, the ratio of equity attributable to owners of the parent was 58.2% (down 3.9 percentage points from the end of the previous fiscal year). [Cash Flows] ○ Net cash from operating activities amounted to an outflow of ¥2.6 billion (inflow of ¥1.1 billion in the same period of previous fiscal year). Working capital increased due to an increase in accounts receivable and inventories for Leqembi and others. ○ N et cash used in investing activities amounted to an inflow of ¥6.5 billion (outflow of ¥9.4 billion in the same period of previous fiscal year), mainly due to proceeds from the sale of financial assets. ○ Net cash from financing activities amounted to an inflow of ¥57.9 billion (up ¥31.8 billion from the same period of previous fiscal year). While dividends were paid, inflow from bonds and short-term borrowings increased. ○ As a result of the above, cash and cash equivalents as of the end of the period stood at 4
Page 7
¥311.7 billion (up ¥66.3 billion from the end of the previous fiscal year). Free cash flow (cash flow from operating activities excluding capital expenditures) for the year was an inflow of ¥4.0 billion. (3) Research & Development Pipeline, Alliances, and Other Events [Status of Ongoing Research & Development Pipelines] 〇 Anticancer agent Lenvima (lenvatinib, jointly developed with Merck & Co., Inc., Rahway, NJ, USA) Approved as a monotherapy for use in the treatment of thyroid cancer and hepatocellular carcinoma (first-line) mainly in Japan, the United States, Europe, China and Asia. Approved as a monotherapy for use in the treatment of unresectable thymic carcinoma in Japan and Asia. Approved in combination with everolimus for use in the treatment of renal cell carcinoma (second-line) mainly in the United States, Europe and Asia. Approved in combination with pembrolizumab, Merck & Co., Inc., Rahway, NJ, USA’s anti-PD-1 therapy, f or use in the treatment of renal cell carcinoma (first-line) and endometrial carcinoma (following prior systemic therapy) mainly in Japan, the United States, Europe and Asia. Approved in combination with pembrolizumab and transcatheter arterial chemoembolization (TACE) for hepatocellular carcinoma in China. Regarding a combination treatment with Merck & Co., Inc., Rahway, NJ, USA’ s oral hypoxia-inducible factor -2 alpha (HIF-2 α) inhibitor belzutifan, applications have been submitted seeking approval for advanced renal cell carcinoma in Japan and the United States, and the Prescription Drug User Fee Act (PDUFA) action date in the United States is set for October 4, 2026. In April 2026, regarding the triplet therapy with Merck & Co., Inc., Rahway, NJ, USA’ s pembrolizumab and belzutifan, at a pre-specified interim analysis of the Phase III clinical study conducted by Merck & Co., Inc., Rahway, NJ, USA for advanced renal cell carcinoma (first-line), the triplet regimen did not meet the dual primary endpoints of overall survival (OS) and progression- free survival (PFS) compared to pembrolizumab plus Lenvima. 〇 AD treatment Leqembi (lecanemab, jointly developed with Biogen Inc. (U.S.)) A pproved as a treatment for early AD in 53 countries and regions including Japan, the United States, China, Europe, and Asia, with applications submitted in 6 countries. A pproved for once every four weeks intravenous maintenance treatment after an 18- month initiation phase with once every two weeks treatment in 8 countries including the United States and China, with applications submitted in 12 countries and regions including Europe (EU). Approved as a subcutaneous autoinjector (SC-AI) for maintenance treatment (360mg, once weekly) in the United States. In July 2026, initiation treatment by SC- AI (500mg, once weekly) was approved in the United States, with applications submitted in 4 countries including Japan and China. In China, the application has been granted priority review designation. 5
Page 8
AHEAD 3 -45 (Phase III study) for preclinical (asymptomatic) AD is underway in partnership with the Alzheimer's Clinical Trials Consortium (ACTC) in countries including Japan, the United States and Europe. 〇 Insomnia treatment Dayvigo (lemborexant) Approved for the treatment of insomnia mainly in Japan, the United States , China and Asia. In June 2026, a Marketing Authorisation Application was accepted in the United Kingdom for the treatment of adult patients with insomnia, characterized by symptoms present for at least 3 months with considerable impact on daytime functioning. In July 2026, a Marketing Authorisation Application was accepted in Europe (EU) for the treatment of adult patients with chronic insomnia. ○ Regarding anticancer agent taletre ctinib, a Marketing Authorisation Application for the treatment of advanced ROS1- positive (ROS1+) non- small cell lung cancer (NSCLC) was accepted in the United Kingdom in June 2026. [Major Alliances and Agreements] ○ In June 2026, Eisai entered into a partnership with Mitsubishi UFJ Trust and Banking Corporation (Tokyo) to provide information on cognitive function as part of initiatives aimed at dementia prevention. ○ In June 2026, Eisai announced that it has signed an agreement with University College London to extend the partnership on drug discovery and development research for neurodegenerative diseases until 2030. ○ In July 2026, Eisai announced that it will commence the co-promotion of Nurtec OD Tablet 75mg (rimegepant), manufactured and marketed by Pfizer Japan Inc. (Tokyo), for acute treatment and prophylaxis of migraine in Japan from September 2026. [Other Events] ○ In May 2026, Eisai was selected for the highest rating of Supplier Engagement Leader in the Supplier Engagement Rating by the non-profit organization CDP (the United Kingdom). This is the second consecutive year that Eisai has been selected. ○ In June 2026, Eisai issued ¥50.0 billion of unsecured straight bonds to diversify its financing sources for growth investments. ○ In June 2026, Eisai announced a strategic investment supported by the United Kingdom Government under the Life Sciences Innovative Manufacturing Fund (LSIMF), subject to terms and conditions, at its manufacturing site in Hatfield, United Kingdom, to establish supply chain and packaging capabilities for current and future medicines that require cold- chain management, including lecanemab. 6
Page 9
(4) Information on Outlook for the Future including Financial Forecast (April 1, 2026 – March 31, 2027) [Consolidated Financial Forecast] ○ There are no changes to the consolidated financial forecast announced on May 15, 2026. FY2025 FY2026 Forecast % Change Revenue ¥825.4 billion ¥883.5 billion +7.0% Operating profit ¥44.1 billion ¥70.0 billion +58.6% Profit before income taxes ¥51.0 billion ¥74.0 billion +45.1% Profit for the year ¥40.5 billion ¥54.0 billion +33.3% Profit for the year attributable to owners of the parent ¥38.6 billion ¥52.3 billion +35.6% Earnings per share attributable to owners of the parent (basic) ¥136.78 ¥185.00 +35.3% Core operating profit ¥50.1 billion ¥70.0 billion +39.8% (Assumptions: 1 USD = ¥153.0, 1 EUR = ¥180.0, 1 GBP = ¥205.0, 1 RMB = ¥22.5) [Forecasts and Risk Factors] The materials and information provided in this announcement include current forecasts, targets, evaluations, estimates, assumptions that are accompanied by risks, and other matters that are based on uncertain factors. Accordingly, it is possible that actual results will deviate significantly from forecasts, etc., due to changes to a variety of factors. These risks and uncertainties include general industry and market conditions, changes in tariff policies in various countries, fluctuation of interest rates and currency exchange rates, and other aspects of economic conditions in Japan and internationally. For further details on risks and uncertainties that could cause significant fluctuations in the results of the Group or have a material effect on investment decisions, please refer to the “ Risk Factors” section of the Annual Securities Report in the previous fiscal year. However, these do not cover all of the risks and uncertainties faced by the Group, and it is possible that they will be affected in the future by other factors that cannot be foreseen, or are not deemed to be important, at this point in time. These are judgments as of the time of the announcement, and statements in the text regarding the future are not guarantees that they will occur or be achieved. 7
Page 10
(Millions of yen) Three-month period ended June 30, 2026 Three-month period ended June 30, 2025 Revenue 234,330 202,651 Cost of sales (51,089) (42,600) Gross profit 183,241 160,051 Selling, general and administrative expenses (114,827) (100,164) Research and development expenses (43,713) (38,792) Other income 507 262 Other expenses (479) (615) Operating profit 24,728 20,744 Financial income 2,512 2,577 Financial costs (1,956) (916) Profit before income taxes 25,283 22,404 Income taxes (6,132) (7,068) Profit for the period 19,151 15,337 Profit for the period attributable to Owners of the parent 18,242 14,474 Non-controlling interests 909 862 Earnings per share Basic (yen) 64.71 51.35 Diluted (yen) － － 2. Condensed Interim Consolidated Financial Statements and Major Notes (1) Condensed Interim Consolidated Statement of Income 8
Page 11
(Millions of yen) Three-month period ended June 30, 2026 Three-month period ended June 30, 2025 Profit for the period 19,151 15,337 Other comprehensive income (loss) Items that will not be reclassified to profit or loss Financial assets measured at fair value through other comprehensive income (loss) (2,331) 3,036 Subtotal (2,331) 3,036 Items that may be reclassified subsequently to profit or loss Exchange differences on translation of foreign operations 14,381 (7,293) Cash flow hedges (24) (12) Subtotal 14,356 (7,305) Total other comprehensive income (loss), net of tax 12,025 (4,270) Comprehensive income (loss) for the period 31,177 11,067 Comprehensive income (loss) for the period attributable to Owners of the parent 30,262 10,214 Non-controlling interests 915 853 (2) Condensed Interim Consolidated Statement of Comprehensive Income 9
Page 12
(Millions of yen) As of June 30, 2026 As of March 31, 2026 Assets Non-current assets Property, plant and equipment 159,726 161,042 Goodwill 263,151 259,200 Intangible assets 85,624 88,125 Other financial assets 50,207 62,412 Other assets 8,609 8,658 Deferred tax assets 107,760 108,039 Total non-current assets 675,078 687,477 Current assets Inventories 282,008 257,547 Trade and other receivables 253,125 227,002 Other financial assets 1,576 892 Other assets 34,565 30,773 Cash and cash equivalents 311,739 245,423 Total current assets 883,013 761,637 Total assets 1,558,091 1,449,113 (3) Condensed Interim Consolidated Statement of Financial Position 10
Page 13
(Millions of yen) As of June 30, 2026 As of March 31, 2026 Equity Equity attributable to owners of the parent Share capital 44,986 44,986 Capital surplus 74,188 74,307 Treasury shares (42,290) (42,288) Retained earnings 504,261 510,919 Other components of equity 325,419 311,068 Total equity attributable to owners of the parent 906,564 898,992 Non-controlling interests 26,606 26,131 Total equity 933,169 925,124 Liabilities Non-current liabilities Bonds and Borrowings 184,604 134,777 Other financial liabilities 33,595 33,806 Provisions 1,579 1,584 Other liabilities 9,527 11,887 Deferred tax liabilities 1,974 1,682 Total non-current liabilities 231,279 183,736 Current liabilities Bonds and Borrowings 86,738 51,304 Trade and other payables 87,531 75,892 Other financial liabilities 22,106 16,264 Income taxes payable 6,212 6,672 Provisions 51,877 46,632 Other liabilities 139,178 143,489 Total current liabilities 393,642 340,254 Total liabilities 624,922 523,990 Total equity and liabilities 1,558,091 1,449,113 11
Page 14
(Millions of yen) Equity attributable to owners of the parent Share capital Capital surplus Treasury shares Retained earnings Other components of equity Financial assets measured at fair value through other comprehensive income (loss) As of April 1, 2026 44,986 74,307 (42,288) 510,919 － Profit for the period － － － 18,242 － Total other comprehensive income (loss) － － － － (2,331) Comprehensive income (loss) for the period － － － 18,242 (2,331) Dividends － － － (22,569) － Acquisition of treasury shares － － (2) － － Changes in ownership interest in subsidiaries － (119) － － － Reclassification － － － (2,331) 2,331 Total transactions with owners － (119) (2) (24,900) 2,331 As of June 30, 2026 44,986 74,188 (42,290) 504,261 － Equity attributable to owners of the parent Non-controlling interests Total equity Other components of equity Total equity attributable to owners of the parent Exchange differences on translation of foreign operations Cash flow hedges Total other components of equity As of April 1, 2026 311,029 40 311,068 898,992 26,131 925,124 Profit for the period － － － 18,242 909 19,151 Total other comprehensive income (loss) 14,375 (24) 12,020 12,020 6 12,025 Comprehensive income (loss) for the period 14,375 (24) 12,020 30,262 915 31,177 Dividends － － － (22,569) (560) (23,129) Acquisition of treasury shares － － － (2) － (2) Changes in ownership interest in subsidiaries － － － (119) 119 － Reclassification － － 2,331 － － － Total transactions with owners － － 2,331 (22,690) (440) (23,131) As of June 30, 2026 325,404 15 325,419 906,564 26,606 933,169 (4) Condensed Interim Consolidated Statement of Changes in Equity For the three-month period ended June 30, 2026 12
Page 15
(Millions of yen) Equity attributable to owners of the parent Share capital Capital surplus Treasury shares Retained earnings Other components of equity Financial assets measured at fair value through other comprehensive income (loss) As of April 1, 2025 44,986 74,843 (42,294) 511,917 － Profit for the period － － － 14,474 － Total other comprehensive income (loss) － － － － 3,036 Comprehensive income (loss) for the period － － － 14,474 3,036 Dividends － － － (22,569) － Acquisition of treasury shares － － (3) － － Disposal of treasury shares － (0) 0 － － Acquisition of subsidiaries － － － － － Changes in ownership interest in subsidiaries － (552) － － － Reclassification － － － 3,036 (3,036) Total transactions with owners － (552) (3) (19,534) (3,036) As of June 30, 2025 44,986 74,291 (42,297) 506,858 － Equity attributable to owners of the parent Non-controlling interests Total equity Other components of equity Total equity attributable to owners of the parent Exchange differences on translation of foreign operations Cash flow hedges Total other components of equity As of April 1, 2025 251,796 169 251,965 841,417 24,551 865,968 Profit for the period － － － 14,474 862 15,337 Total other comprehensive income (loss) (7,283) (12) (4,260) (4,260) (10) (4,270) Comprehensive income (loss) for the period (7,283) (12) (4,260) 10,214 853 11,067 Dividends － － － (22,569) (513) (23,083) Acquisition of treasury shares － － － (3) － (3) Disposal of treasury shares － － － 0 － 0 Acquisition of subsidiaries － － － － 179 179 Changes in ownership interest in subsidiaries － － － (552) (44) (596) Reclassification － － (3,036) － － － Total transactions with owners － － (3,036) (23,124) (379) (23,503) As of June 30, 2025 244,512 157 244,669 828,507 25,025 853,532 For the three-month period ended June 30, 2025 13
Page 16
(Millions of yen) For the three-month period ended June 30, 2026 For the three-month period ended June 30, 2025 Operating activities Profit before income taxes 25,283 22,404 Depreciation and amortization 9,420 9,697 Impairment losses － 1,309 (Increase) decrease in working capital (29,725) (25,972) Interest and dividends received 1,965 2,102 Interest paid (1,214) (879) Income taxes paid (6,741) (4,331) Other (1,575) (3,236) Net cash from (used in) operating activities (2,588) 1,094 Investing activities Purchases of property, plant and equipment (4,259) (4,534) Purchases of intangible assets (963) (2,597) Proceeds from sale of property, plant and equipment and intangible assets 1,906 113 Net cash outflow on acquisition of subsidiaries － (12,584) Purchases of financial assets (974) (196) Proceeds from sale and redemption of financial assets 10,909 10,473 Payments of time deposits exceeding three months － (1) Proceeds from redemption of time deposits exceeding three months － 0 Other (161) (44) Net cash from (used in) investing activities 6,457 (9,369) Financing activities Net increase (decrease) in short-term borrowings 34,010 51,677 Proceeds from issuance of bonds and long-term borrowings 50,000 － Redemption of bonds and repayments of long-term borrowings (2) (2) Repayments of lease liabilities (2,764) (2,585) Dividends paid (22,569) (22,569) Other (750) (425) Net cash from (used in) financing activities 57,925 26,095 Effect of exchange rate change on cash and cash equivalents 4,522 2,000 Net increase (decrease) in cash and cash equivalents 66,316 19,819 Cash and cash equivalents at beginning of period 245,423 265,561 Cash and cash equivalents at end of period 311,739 285,380 (5) Condensed Interim Consolidated Statement of Cash Flows 14
Page 17
(6) Notes to Condensed Interim Consolidated Financial Statements (Going Concern) Not applicable Accounting standards and interpretations Mandatory application (Date of commencement) To be applied by the Group Description IFRS 7 IFRS 9 Financial Instruments: Disclosures Financial Instruments January 1, 2026 Fiscal year ending March 31, 2027 • Clarification of accounting and disclosures related to contracts referencing nature-dependent electricity • Clarification of the classification of financial assets containing ESG-linked and similar features (Changes in Accounting Policies) With the exception of the following, all material accounting policies that are applied to these condensed interim consolidated financial statements for this period are the same as those that were applied to the consolidated financial statements for the previous fiscal year. None of the following accounting standards and interpretations applied by the Group has any major impact on the condensed interim consolidated financial statements for this period. 15
Page 18
(Millions of yen) Three-month period ended June 30, 2026 Three-month period ended June 30, 2025 Revenue Segment profit (loss) Revenue Segment profit (loss) Pharmaceutical business Japan 57,940 21,032 56,048 19,448 Americas 86,576 51,936 70,801 41,540 China 42,527 21,178 36,461 17,917 EMEA 23,646 12,451 19,007 8,200 East Asia Global South 20,212 9,481 16,130 8,241 Reporting segment total 230,901 116,079 198,448 95,347 Other business (Note 1) 3,429 1,251 4,203 2,234 Total 234,330 117,330 202,651 97,581 R&D expenses (Note 2) － (38,883) － (34,239) Group headquarters’ management costs and other expenses (Note 3) － (53,719) － (42,598) Operating profit in the condensed interim consolidated statement of income － 24,728 － 20,744 (Segment Information) Reporting segments are units for which the Group can obtain independent financial information and for which top management undertakes periodic reviews in order to determine the allocation of management resources and evaluate performance. The Group’s business is comprised of pharmaceutical business and other business. The pharmaceutical business is organized into the following five reporting segments in this report: Japan, Americas (North America), China, EMEA (Europe, the Middle East, Africa, Russia and Oceania), and East Asia Global South (primarily South Korea, Taiwan, India, ASEAN, Central and South America, and South Africa). (Note 1) “Other business” mainly includes the license revenue and pharmaceutical ingredient business of the parent company. (Note 2) “R&D expenses” do not include expenses associated with medical activities, which are reflected in each reporting segment. (Note 3) “Group headquarters’ management costs and other expenses” are the costs and expenses covering Group-wide operations which include the amount of other income and expenses, and the amount of profits and expenses shared under strategic collaborations with partners. For the three-month period ended June 30, 2026, shared profit of ¥44,252 million (¥36,022 million for the three-month period ended June 30, 2025) for anticancer agent Lenvima paid by the Group to Merck & Co., Inc., Rahway, NJ, USA was included in Group headquarters’ management costs and other expenses. 16
Page 19
(Consolidated Statement of Income) (1) Selling, general and administrative expenses (SG&A expenses) For the three-month period ended June 30, 2026, the Group recognized shared profit of ¥44,252 million (¥36,022 million for the three-month period ended June 30, 2025) for anticancer agent Lenvima paid by the Group to Merck & Co., Inc., Rahway, NJ, USA as SG&A expenses. (Consolidated Statement of Cash Flows) (1) Net cash outflow on acquisition of subsidiaries For the three-month period ended June 30, 2025, net cash outflow on acquisition of subsidiaries of ¥12,584 million was due to the acquisition of shares of EcoNaviSta, Inc. (Significant Subsequent Events) Not applicable 17